Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is family medicine physicians, internists, allergists, immunologists, gastroenterologists, otolaryngologists, pulmonologists, and other health care professionals involved in the management of patients with chronic cough.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

• Outline multidisciplinary strategies that can streamline the health care journey for patients with chronic cough.
• Review the latest mechanistic understanding regarding chronic cough and the implications for emerging treatments.
• Evaluate the latest clinical evidence regarding emerging treatment strategies for patients with chronic cough.

Activity Description

In this educational video, experts examine the patient's health care journey and discuss multidisciplinary approaches to assessment and management of chronic cough. Faculty will review current unmet needs and discuss emerging treatment options to improve the quality of life for patients with refractory chronic cough. This expert panel features an interactive learning platform to encourage engagement and enhanced learning.

Statement of Educational Need

Chronic cough lasting more than 8 weeks impacts up to 13% of the US population. While chronic cough may be associated with any number of pulmonary or extrapulmonary conditions, 70% of patients with chronic cough experience at least 3 clinical encounters to obtain a diagnosis and 53% remain undiagnosed. Additionally, over half of patients who receive treatment note that their symptoms remain uncontrolled, significantly affecting daily activities, sleep, and quality of life. With new treatments on the horizon for managing chronic cough, it is imperative that clinicians have a mechanistic understanding of chronic cough and are able to identify patients who may benefit from emerging therapies.

Agenda

A Look at the Health Care Journey of Patients With Chronic Cough
John J. Russell, MD, FAAFP

Current Unmet Needs in Chronic Cough
Kenneth W. Altman, MD, PhD, FACS

Treatments on the Horizon for Refractory Chronic Cough
Peter Dicpinigaitis, MD, FCCP

Activity Chair

Peter Dicpinigaitis, MD, FCCP
Professor of Medicine, Albert Einstein College of Medicine
Division of Critical Care Medicine, Montefiore Medical Center
Director, Montefiore Cough Center
Bronx, NY

Disclosures:
Consulting Fee: Bayer, Bellus, Merck, Shionogi

Faculty

Kenneth W. Altman, MD, PhD, FACS
Chair, Department of Otolaryngology – Head & Neck Surgery
Geisinger Health System
Danville, PA
Professor, Geisinger Commonwealth School of Medicine
Scranton, PA

Disclosures:
Consulting Fee: AXDEV

John J. Russell, MD, FAAFP
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA

Disclosures:
Consulting Fee: Bayer, GlaxoSmithKline, Sanofi Pasteur
Speakers Bureau: Sanofi Pasteur

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

• 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program; and
• 1.0 Part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program (formerly known as MOC).

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABOHNS credit.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is family medicine physicians, internists, allergists, immunologists, gastroenterologists, otolaryngologists, pulmonologists, and other health care professionals involved in the management of patients with chronic cough.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

• Outline multidisciplinary strategies that can streamline the health care journey for patients with chronic cough.
• Review the latest mechanistic understanding regarding chronic cough and the implications for emerging treatments.
• Evaluate the latest clinical evidence regarding emerging treatment strategies for patients with chronic cough.

Activity Description

In this educational video, experts examine the patient's health care journey and discuss multidisciplinary approaches to assessment and management of chronic cough. Faculty will review current unmet needs and discuss emerging treatment options to improve the quality of life for patients with refractory chronic cough. This expert panel features an interactive learning platform to encourage engagement and enhanced learning.

Statement of Educational Need

Chronic cough lasting more than 8 weeks impacts up to 13% of the US population. While chronic cough may be associated with any number of pulmonary or extrapulmonary conditions, 70% of patients with chronic cough experience at least 3 clinical encounters to obtain a diagnosis and 53% remain undiagnosed. Additionally, over half of patients who receive treatment note that their symptoms remain uncontrolled, significantly affecting daily activities, sleep, and quality of life. With new treatments on the horizon for managing chronic cough, it is imperative that clinicians have a mechanistic understanding of chronic cough and are able to identify patients who may benefit from emerging therapies.

Agenda

A Look at the Health Care Journey of Patients With Chronic Cough
John J. Russell, MD, FAAFP

Current Unmet Needs in Chronic Cough
Kenneth W. Altman, MD, PhD, FACS

Treatments on the Horizon for Refractory Chronic Cough
Peter Dicpinigaitis, MD, FCCP

Activity Chair

Peter Dicpinigaitis, MD, FCCP
Professor of Medicine, Albert Einstein College of Medicine
Division of Critical Care Medicine, Montefiore Medical Center
Director, Montefiore Cough Center
Bronx, NY

Disclosures:
Consulting Fee: Bayer, Bellus, Merck, Shionogi

Faculty

Kenneth W. Altman, MD, PhD, FACS
Chair, Department of Otolaryngology – Head & Neck Surgery
Geisinger Health System
Danville, PA
Professor, Geisinger Commonwealth School of Medicine
Scranton, PA

Disclosures:
Consulting Fee: AXDEV

John J. Russell, MD, FAAFP
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA

Disclosures:
Consulting Fee: Bayer, GlaxoSmithKline, Sanofi Pasteur
Speakers Bureau: Sanofi Pasteur

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

• 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program; and
• 1.0 Part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program (formerly known as MOC).

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABOHNS credit.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Oncologists, pulmonologists, and other healthcare professionals involved in the treatment of patients with NSCLC.

Learning Objective

After completing this activity, the clinician should be able to:

• Assess the relationship between checkpoint inhibitor mechanism of action and differential safety profile versus chemotherapy

Activity Description

This 15-minute infographic activity uses an interactive approach augmented by a whiteboard animation and clinician videos to delineate checkpoint inhibitor mechanisms of action, key safety points, and important aspects of patient counseling.

Chair

Ahmet Sezer, MD
Professor, Medical Oncology
Başkent University
Adana, Turkey

Faculty

Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT

Brian Henick, MD
Assistant Professor of Medicine at CUIMC
Columbia University Irving Medical Center
New York, NY

Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Ahmet Sezer, MD, has no financial relationships to disclose.

Sarah B. Goldberg, MD, MPH, has affiliations with AstraZeneca, Blueprint Medicine, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consulting Fees); AstraZeneca, Boehringer Ingelheim (Contracted Research).

Brian Henick, MD, has no financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH CE Director of Accreditations, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Yael Waknine, Medical Director, has no financial relationships to disclose.
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
David Reilly, MSc, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria For Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 50% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation

In order to claim MOC points, users must:

• Review and successfully complete the activity
• Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Activity Details

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Oncologists, pulmonologists, and other healthcare professionals involved in the treatment of patients with NSCLC.

Learning Objective

After completing this activity, the clinician should be able to:

• Assess the relationship between checkpoint inhibitor mechanism of action and differential safety profile versus chemotherapy

Activity Description

This 15-minute infographic activity uses an interactive approach augmented by a whiteboard animation and clinician videos to delineate checkpoint inhibitor mechanisms of action, key safety points, and important aspects of patient counseling.

Chair

Ahmet Sezer, MD
Professor, Medical Oncology
Başkent University
Adana, Turkey

Faculty

Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT

Brian Henick, MD
Assistant Professor of Medicine at CUIMC
Columbia University Irving Medical Center
New York, NY

Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Ahmet Sezer, MD, has no financial relationships to disclose.

Sarah B. Goldberg, MD, MPH, has affiliations with AstraZeneca, Blueprint Medicine, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consulting Fees); AstraZeneca, Boehringer Ingelheim (Contracted Research).

Brian Henick, MD, has no financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH CE Director of Accreditations, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Yael Waknine, Medical Director, has no financial relationships to disclose.
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
David Reilly, MSc, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria For Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 50% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation

In order to claim MOC points, users must:

• Review and successfully complete the activity
• Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Activity Details

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.^1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.^3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.⁶ Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.⁷

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
6. Moorman JE, et al. Vital Health Stat 3. 2012;35:1-58.
7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objective

• Describe the clinical profiles of and prescribing considerations for biologic therapies in the treatment of moderate-to-severe asthma

Faculty

Monica Kraft, MD
Professor, Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 100% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Monica Kraft, MD
Consultant/Independent Contractor: AstraZeneca plc, sanofi-aventis U.S. LLC
Grant/Research Support: AstraZeneca plc, Chiesi USA, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.^1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.^3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.⁶ Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.⁷

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
6. Moorman JE, et al. Vital Health Stat 3. 2012;35:1-58.
7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objective

• Describe the clinical profiles of and prescribing considerations for biologic therapies in the treatment of moderate-to-severe asthma

Faculty

Monica Kraft, MD
Professor, Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 100% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Monica Kraft, MD
Consultant/Independent Contractor: AstraZeneca plc, sanofi-aventis U.S. LLC
Grant/Research Support: AstraZeneca plc, Chiesi USA, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Accredited By

This activity is provided by Global Education Group. Produced in collaboration with RMEI Medical Education, LLC.

Target Audience

This activity is designed to meet the educational needs of medical and surgical oncologists, pathologists, oncology NPs and PAs, and pulmonologists who diagnose and manage patients with breast cancer, non-small cell lung cancer (NSCLC), and/or gastric cancer.

Learning Objectives

Upon completion of this activity, the clinician should be able to:

• Employ available data on newly approved and investigational HER2- and HER3-directed therapies for advanced breast cancer 
• Assess the therapeutic potential role and place of HER2- and HER3-targeted agents in non-small cell lung cancer (NSCLC) 
• Apply current evidence for new frontline combinations in HER2+ advanced gastric cancer, as well as new and emerging options for refractory disease 

Activity Description

During this Clinical Forum℠ activity, 3 nationally recognized experts in the management of solid tumors discuss approved and emerging therapeutic approaches targeting HER2 or HER3 in patients with breast cancer, non-small cell lung cancer (NSCLC), and gastric cancer.

Statement of Educational Need

Clinical research seeks to expand the treatment armamentarium for solid tumors by investigating new or emerging HER2-targeted therapies in breast, lung, and gastric cancer; targeting HER3 and other escape mechanisms are also of interest. Given the rapidly evolving landscape of HER2-targeted therapies and the emerging role of HER3, clinicians require clear knowledge of the latest advances in order to deliver optimal cancer care.

Faculty

Sara M. Tolaney, MD, MPH
Associate Director, Susan F. Smith Center for Women’s Cancer
Director, Clinical Trials, Breast Oncology Center
Senior Physician
Dana-Farber Cancer Institute
Associate Professor, Medicine
Harvard Medical School
Boston, MA

Daniel Catenacci, MD
Associate Professor, Department of Medicine, Section of Hematology & Oncology
Director, Interdisciplinary Gastrointestinal Oncology Program
Assistant Director, Translational Research, Comprehensive Cancer Center
The University of Chicago Medical Center & Biological Sciences
Chicago, IL

Liza C. Villaruz, MD
Associate Professor, Medicine
UPMC Hillman Cancer Center
University of Pittsburgh
Pittsburgh, PA 

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Sara M. Tolaney, MD, MPH
Consultant: AstraZeneca, Athenex, Bristol-Myers Squibb, Certara, CytomX, Daiichi Sankyo, Eisai, Eli Lilly, G1 Therapeutics, Genentech/Roche, Immunomedics/Gilead, Kyowa Kirin Pharmaceutics, Merck, Mersana Therapeutics, Nanostring, Nektar, Novartis, Odonate, OncoPep, OncoSec, Pfizer, Puma, Samsung Bioepsis, Sanofi, SeaGen.
Contracted Research: AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Eli Lilly, Exelixis, Genentech/Roche, Immunomedics/Gilead, Merck, Nanostring, Nektar, Novartis, Odonate, Pfizer, Sanofi, SeaGen.
 
Daniel Catenacci, MD
Consultant: Amgen, Archer & Natera, Arcus, Astellas, Basilea, BMS, Daiichi Sankyo, Eli Lilly, Five Prime, Foundation Medicine, Genentech/Roche, Gritstone, Guardant Health, Merck, Pieris, QED, Seattle Genetics, Taiho, Tempus, Zymeworks.
Honoraria: Amgen, Archer & Natera, Arcus, Astellas, Basilea, BMS, Daiichi Sankyo, Eli Lilly, Five Prime, Foundation Medicine, Genentech/Roche, Gritstone, Guardant Health, Merck, Pieris, QED, Seattle Genetics, Taiho, Tempus, Zymeworks.
Speaker’s Bureau: Daiichi Sankyo, Eli Lilly, Genentech/Roche, Guardant Health, Merck, Tempus.  

Liza C. Villaruz, MD, has nothing to disclose.  

The planners and managers have the following relevant financial relationships with ineligible companies:
  
Lindsay Borvansky has nothing to disclose. 
Andrea Funk has nothing to disclose. 
Liddy Knight has nothing to disclose. 
Ashley Cann has nothing to disclose. 
Agnes Yang has nothing to disclose. 
Sharon Powell has nothing to disclose. 
Elizabeth Johnson has nothing to disclose.  

Accreditation Statement

Physician Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on May 12, 2021 and is valid for one year. Requests for credit must be made no later than May 11, 2022.

In order to receive credit for this activity, the participant must:

• Read the learning objectives and faculty disclosures.
• Participate in the activity.
• Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) does not recommend the use of any agent outside of the labeled indications.     

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com. 

Activity Details

Accredited By

This activity is provided by Global Education Group. Produced in collaboration with RMEI Medical Education, LLC.

Target Audience

This activity is designed to meet the educational needs of medical and surgical oncologists, pathologists, oncology NPs and PAs, and pulmonologists who diagnose and manage patients with breast cancer, non-small cell lung cancer (NSCLC), and/or gastric cancer.

Learning Objectives

Upon completion of this activity, the clinician should be able to:

• Employ available data on newly approved and investigational HER2- and HER3-directed therapies for advanced breast cancer 
• Assess the therapeutic potential role and place of HER2- and HER3-targeted agents in non-small cell lung cancer (NSCLC) 
• Apply current evidence for new frontline combinations in HER2+ advanced gastric cancer, as well as new and emerging options for refractory disease 

Activity Description

During this Clinical Forum℠ activity, 3 nationally recognized experts in the management of solid tumors discuss approved and emerging therapeutic approaches targeting HER2 or HER3 in patients with breast cancer, non-small cell lung cancer (NSCLC), and gastric cancer.

Statement of Educational Need

Clinical research seeks to expand the treatment armamentarium for solid tumors by investigating new or emerging HER2-targeted therapies in breast, lung, and gastric cancer; targeting HER3 and other escape mechanisms are also of interest. Given the rapidly evolving landscape of HER2-targeted therapies and the emerging role of HER3, clinicians require clear knowledge of the latest advances in order to deliver optimal cancer care.

Faculty

Sara M. Tolaney, MD, MPH
Associate Director, Susan F. Smith Center for Women’s Cancer
Director, Clinical Trials, Breast Oncology Center
Senior Physician
Dana-Farber Cancer Institute
Associate Professor, Medicine
Harvard Medical School
Boston, MA

Daniel Catenacci, MD
Associate Professor, Department of Medicine, Section of Hematology & Oncology
Director, Interdisciplinary Gastrointestinal Oncology Program
Assistant Director, Translational Research, Comprehensive Cancer Center
The University of Chicago Medical Center & Biological Sciences
Chicago, IL

Liza C. Villaruz, MD
Associate Professor, Medicine
UPMC Hillman Cancer Center
University of Pittsburgh
Pittsburgh, PA 

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Sara M. Tolaney, MD, MPH
Consultant: AstraZeneca, Athenex, Bristol-Myers Squibb, Certara, CytomX, Daiichi Sankyo, Eisai, Eli Lilly, G1 Therapeutics, Genentech/Roche, Immunomedics/Gilead, Kyowa Kirin Pharmaceutics, Merck, Mersana Therapeutics, Nanostring, Nektar, Novartis, Odonate, OncoPep, OncoSec, Pfizer, Puma, Samsung Bioepsis, Sanofi, SeaGen.
Contracted Research: AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Eli Lilly, Exelixis, Genentech/Roche, Immunomedics/Gilead, Merck, Nanostring, Nektar, Novartis, Odonate, Pfizer, Sanofi, SeaGen.
 
Daniel Catenacci, MD
Consultant: Amgen, Archer & Natera, Arcus, Astellas, Basilea, BMS, Daiichi Sankyo, Eli Lilly, Five Prime, Foundation Medicine, Genentech/Roche, Gritstone, Guardant Health, Merck, Pieris, QED, Seattle Genetics, Taiho, Tempus, Zymeworks.
Honoraria: Amgen, Archer & Natera, Arcus, Astellas, Basilea, BMS, Daiichi Sankyo, Eli Lilly, Five Prime, Foundation Medicine, Genentech/Roche, Gritstone, Guardant Health, Merck, Pieris, QED, Seattle Genetics, Taiho, Tempus, Zymeworks.
Speaker’s Bureau: Daiichi Sankyo, Eli Lilly, Genentech/Roche, Guardant Health, Merck, Tempus.  

Liza C. Villaruz, MD, has nothing to disclose.  

The planners and managers have the following relevant financial relationships with ineligible companies:
  
Lindsay Borvansky has nothing to disclose. 
Andrea Funk has nothing to disclose. 
Liddy Knight has nothing to disclose. 
Ashley Cann has nothing to disclose. 
Agnes Yang has nothing to disclose. 
Sharon Powell has nothing to disclose. 
Elizabeth Johnson has nothing to disclose.  

Accreditation Statement

Physician Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on May 12, 2021 and is valid for one year. Requests for credit must be made no later than May 11, 2022.

In order to receive credit for this activity, the participant must:

• Read the learning objectives and faculty disclosures.
• Participate in the activity.
• Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) does not recommend the use of any agent outside of the labeled indications.     

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.